Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence

Fung, Simon; Blair, Hannah A.

doi:10.1007/s11523-023-00952-y

Cited by 2 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It further underscores that Ki-67 serves as both a prognostic and predictive marker in breast cancer, elevating its significance beyond a routine immunostain. 4,25 However, a pertinent question remains about the establishment of uniform reporting for Ki-67 and the definition of cutoff values for low and high Ki-67 indices, which would facilitate the stratification of patient groups. 26 The 2009 St. Gallen recommendations on the treatment of early breast cancer consensus created three groups for Ki-67 levels: Low (≤15%), Intermediate (16% to 30%), and High (≥30%) (Joerger, Senn et al 2009).…”

Section: Use Of Ki-67 In the Breast For Neoadjuvant Therapy: A Benefi...mentioning

confidence: 99%

Artificial intelligence-powered optimization of KI-67 assessment in breast cancer: enhancing precision and workflow efficiency. a literature review

Mehwish Mooghal,

Saba Anjum,

Wajiha Khan

et al. 2024

J Pak Med Assoc

View full text Add to dashboard Cite

Breast Cancer (BC) has evolved from traditional morphological analysis to molecular profiling, identifying new subtypes. Ki-67, a prognostic biomarker, helps classify subtypes and guide chemotherapy decisions. This review explores how artificial intelligence (AI) can optimize Ki-67 assessment, improving precision and workflow efficiency in BC management. The study presents a critical analysis of the current state of AI-powered Ki-67 assessment. Results demonstrate high agreement between AI and standard Ki-67 assessment methods highlighting AI's potential as an auxiliary tool for pathologists. Despite these advancements, the review acknowledges limitations such as the restricted timeframe and diverse study designs, emphasizing the need for further research to address these concerns. In conclusion, AI holds promise in enhancing Ki-67 assessment's precision and workflow efficiency in BC diagnosis. While challenges persist, the integration of AI can revolutionize BC care, making it more accessible and precise, even in resource-limited settings. Keywords: Artificial Intelligence, Ki-67 Antigen, Prognosis, Pathologists, Breast Cancer

show abstract

Section: Use Of Ki-67 In the Breast For Neoadjuvant Therapy: A Benefi...mentioning

confidence: 99%

Artificial intelligence-powered optimization of KI-67 assessment in breast cancer: enhancing precision and workflow efficiency. a literature review

Mehwish Mooghal,

Saba Anjum,

Wajiha Khan

et al. 2024

J Pak Med Assoc

View full text Add to dashboard Cite

show abstract

“…Any ligand did not show skin sensitization properties. Breast cancer [36] Abbreviation: FDA, Food and Drug Administration.…”

Section: Adme Analysis Of the Selected Compoundmentioning

confidence: 99%

Novel chemical scaffold as potential drug against Leishmania donovani: Integrated computational and experimental approaches

Ranjan,

Dubey

2023

J of Cellular Biochemistry

View full text Add to dashboard Cite

In this study, we have screened a large number of Food and Drug Administration‐approved compounds for novel anti‐leishmanial molecules targeting the citrate synthase enzyme of the parasite. Based on their docking and molecular dynamic simulation statistics, five compounds were selected. These compounds followed Lipinski's rule of five. Additionally, in vitro, antileishmanial and cytotoxicity studies were performed. The three compounds, Abemaciclib, Bazedoxifene, and Vorapaxar, had shown effective anti‐leishmanial activities with IC50 values of 0.92 ± 0.02, 0.65 ± 0.09, and 6.1 ± 0.91 against Leishmania donovani promastigote and with EC50 values of 1.52 ± 0.37, 2.11 ± 0.38, 10.4 ± 1.27 against intramacrophagic amastigote without significantly harming macrophage cells. Among them, from in silico and antileishmanial activities studies, Abemaciclib had been selected based on their less binding energy, good antileishmanial activities, and also a significant difference in their binding energy with human citrate synthase for cell death mechanistic studies using flow cytometry and a DNA fragmentation assay. The action of this compound resulted in an increased reactive oxygen species production, depolarization of mitochondrial membrane potential, DNA damage, and an increase in the sub‐G1 cell population. These properties are the hallmarks of apoptosis which were further confirmed by apoptotic assay. Based on the above result, this anticancer compound Abemaciclib could be employed as a potential treatment option for leishmaniasis after further confirmation.

show abstract

Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence

Abstract: This plain language summary represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online.

Cited by 2 publications

References 26 publications

Artificial intelligence-powered optimization of KI-67 assessment in breast cancer: enhancing precision and workflow efficiency. a literature review

Artificial intelligence-powered optimization of KI-67 assessment in breast cancer: enhancing precision and workflow efficiency. a literature review

Novel chemical scaffold as potential drug against Leishmania donovani: Integrated computational and experimental approaches

Contact Info

Product

Resources

About